Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer
Investigators evaluated data from 277 patients with gastric cancer, 180 of whom underwent CRS plus HIPEC vs 97 who underwent CRS only.
Gastrointestinal (GI) Cancers Symposium
Radiotherapy Dose to Lung Affects Overall Survival Among Patients With Esophageal Cancer
Researchers evaluated the outcomes of 453 patients with stage I to III esophageal cancer who received definitive or preoperative chemoradiation.
Aspirin Use Does Not Reduce Risk of Colorectal Cancer Recurrence
There was no evidence that aspirin use beginning at the onset of chemotherapy affected the risk of recurrence among patients with stage II or III colorectal cancer.
Regorafenib Improves Overall Survival in Liver Cancer
Second-line systemic therapy with regorafenib improves overall survival among patients with hepatocellular carcinoma (HCC).
GEMOX Does Not Improve Relapse-free Survival in Biliary Tract Cancer
GEMOX post-surgery adjuvant therapy does not improve relapse-free survival (RFS) among patients with biliary tract cancer.
Advanced Pancreatic Cancer: 3 New Agents Improved Outcomes Between 1978-2015
Phase 2 trials of investigational agents for pancreatic cancer treatment do not usually progress to phase 3.
Bursectomy Not Recommended as Standard Treatment for cT3/T4 Gastric Cancer
Bursectomy can be safely performed without increasing the risk of morbidity or mortality among patients with cT3 or cT4 gastric cancer.
Ramucirumab Efficacious Regardless of Age in Gastric Cancer
For patients with advanced gastric cancer, second-line treatment with ramucirumab is safe and efficacious regardless of age.
Nivolumab Efficacious as Salvage Therapy for Advanced Gastric Cancer
Salvage therapy with nivolumab was efficacious among patients with advanced or recurrent gastric or gastroesophageal junction (GEJ) cancer.
Adding Everolimus to Paclitaxel Not Effective for Advanced Gastric Cancer
The addition of everolimus to paclitaxel did not significantly improve overall response rate, progression-free survival, or overall survival.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in GI Cancers Symposium 2017
Loading... 
Loading...